Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wedzicha, W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wedzicha, W.
Topic Collections
Right arrowRelated Articles
Thorax 2003;58:371
© 2003 BMJ Publishing Group & British Thoracic Society

EDITORIAL

Airwaves

Wisia Wedzicha, Editor in Chief

The first 150 words of the full text of this article appear below.


ß-Defensins and panbronchiolitis
Human ß-defensins (HBD) are now recognised as important antimicrobial peptides forming part of the innate immune system. In this month’s issue of Thorax Hiratsuka and colleagues describe a study of HBD-1 and HBD-2 in plasma and bronchoalveolar lavage (BAL) fluid in patients with diffuse panbronchiolitis (DPB) and compare the findings with human volunteers (HV). DPB is a condition associated with chronic airway inflammation and airway infection. They show that HBD-1 and HBD-2 levels are increased in the BAL fluid of patients with DPB and, in the case of HBD-2, relationships were found with inflammatory cells in the BAL fluid. Macrolide antibiotics are useful as treatment in DPB and this study shows that, after 6 months’ treatment with macrolides, HBD-2 levels in the BAL fluid are reduced. The authors discuss some mechanisms for the airway inflammation in DPB and suggest that ß-defensins—especially HBD-2—may be a useful marker of the condition. See . . . [Full text of this article]


Related Articles

Assessment of illness severity in community acquired pneumonia: a useful new prediction tool?
M Woodhead
Thorax 2003 58: 371-372. [Extract] [Full Text] [PDF]

Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study
W S Lim, M M van der Eerden, R Laing, W G Boersma, N Karalus, G I Town, S A Lewis, and J T Macfarlane
Thorax 2003 58: 377-382. [Abstract] [Full Text] [PDF]

Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus
J B M van Woensel, W M C van Aalderen, W de Weerd, N J G Jansen, J P J van Gestel, D G Markhorst, A J van Vught, A P Bos, and J L L Kimpen
Thorax 2003 58: 383-387. [Abstract] [Full Text] [PDF]

Influence of lung volume reduction surgery (LVRS) on health related quality of life in patients with chronic obstructive pulmonary disease
R S Goldstein, T R J Todd, G Guyatt, S Keshavjee, T E Dolmage, S van Rooy, B Krip, F Maltais, P LeBlanc, S Pakhale, and T K Waddell
Thorax 2003 58: 405-410. [Abstract] [Full Text] [PDF]

Increased concentrations of human ß-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis
T Hiratsuka, H Mukae, H Iiboshi, J Ashitani, K Nabeshima, T Minematsu, N Chino, T Ihi, S Kohno, and M Nakazato
Thorax 2003 58: 425-430. [Abstract] [Full Text] [PDF]

Episodic viral wheeze in preschool children: effect of topical nasal corticosteroid prophylaxis
M Silverman, M Wang, G Hunter, and N Taub
Thorax 2003 58: 431-434. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 BMJ Publishing Group Ltd & British Thoracic Society